Similar to previous reports concerning the molecular profile of advSM, all patients with SM-AML had at least one additional somatic mutation, most frequently affecting TET2, SRSF2, ASXL1, RUNX1, and NPM1. In contrast to de novo AML, only one patient had a FLT3 mutation. This evidence concerns the gene SRSF2 and acute myeloid leukemia.